J Biol Chem, Vol. 274, Issue 38, 27119-27127, September 17, 1999
Quantitative Relationship among Integrin-Ligand Binding,
Adhesion, and Signaling via Focal Adhesion Kinase and Extracellular
Signal-regulated Kinase 2*
Anand R.
Asthagiri
§,
Celeste M.
Nelson
¶,
Alan F.
Horwitz
, and
Douglas A.
Lauffenburger
**
From the
Department of Chemical Engineering, Division
of Bioengineering and Environmental Health, and Center for Cancer
Research, Massachusetts Institute of Technology,
Cambridge, Massachusetts 02139 and the
Department of Cell
Biology, University of Virginia, Charlottesville, Virginia 22908
 |
ABSTRACT |
Because integrin-mediated signals are
transferred through a physical architecture and synergistic biochemical
network whose properties are not well defined, quantitative
relationships between extracellular integrin-ligand binding events and
key intracellular responses are poorly understood. We begin to address
this by quantifying integrin-mediated FAK and ERK2 responses in CHO
cells for varied
5
1 expression
level and substratum fibronectin density. Plating cells on
fibronectin-coated surfaces initiated a transient, biphasic ERK2
response, the magnitude and kinetics of which depended on integrin-ligand binding properties. Whereas ERK2 activity
initially increased with a rate proportional to integrin-ligand bond
number for low fibronectin density, the desensitization rate was
independent of integrin and fibronectin amount but proportional to the
ERK2 activity level with an exponential decay constant of 0.3 (± 0.08) min
1. Unlike the ERK2 activation time course, FAK
phosphorylation followed a superficially disparate time course.
However, analysis of the early kinetics of the two signals revealed
them to be correlated. The initial rates of FAK and ERK2 signal
generation exhibited similar dependence on fibronectin surface density,
with both rates monotonically increasing with fibronectin amount until
saturating at high fibronectin density. Because of this similar initial
rate dependence on integrin-ligand bond formation, the disparity in their time courses is attributed to differences in feedback regulation of these signals. Whereas FAK phosphorylation increased to a
steady-state level as new integrin-ligand bond formation
continued during cell spreading, ERK2 activity was decoupled from the
integrin-ligand stimulus and decayed back to a basal level.
Accordingly, we propose different functional metrics for representing
these two disparate dynamic signals: the steady-state tyrosine
phosphorylation level for FAK and the integral of the pulse response
for ERK2. These measures of FAK and ERK2 activity were found to
correlate with short term cell-substratum adhesivity, indicating that
signaling via FAK and ERK2 is proportional to the number of
integrin-fibronectin bonds.
 |
INTRODUCTION |
Integrins are adhesion receptors that not only provide the
mechanical link between the cell and the extracellular matrix
(ECM)1 that is essential for
adhesion, spreading, and migration (1, 2), but also generate
intracellular signals that affect multiple cell functions (3-5).
Altered cell behavior due to aberrant regulation of these signals
results in pathologies, such as cancer, in which loss of integrin
signaling-based control of cell cycle progression leads to
anchorage-independent cell growth and tumor formation (6). Because of
these significant and wide-ranging regulatory roles, modulating
integrin-mediated signals may provide powerful targets for disease
therapy. Furthermore, since integrins interface cells to biomaterials,
biomimetic surfaces may be designed to instigate appropriate
integrin-mediated signals to elicit desired cell behavior on these
surfaces. However, several issues must be addressed before rational
design can be undertaken for controlled manipulation of these signals
for such applications.
The first such issue derives from the complexity of the multiple
pathways and numerous signaling molecules that connect the extracellular stimulus to intracellular signals. These signals emanate
from focal adhesion complexes, which are formed upon aggregation of
ligand-bound integrins and are composed of intracellular and transmembrane proteins held together by noncovalent intermolecular associations (7). In addition to the poorly characterized physical architecture of these complexes and the mechanisms of its assembly, biophysical phenomena, such as diffusion to and from the plasma membrane and molecular crowding in multiprotein complexes, could inhibit the progress of these pathways (8). Furthermore, the downstream
non-membrane-associated signaling events are highly interconnected, and
clarification of their operational synergy is only beginning to emerge.
Because of the complexity within each hierarchy of events leading to
integrin signals (9), it is not intuitively apparent how the
extracellular ligand binding event quantitatively relates to
intracellular signaling responses. This fundamental relationship is
essential to a better understanding of the cumulative performance of
the synergistic mechanisms underlying integrin-mediated signaling. In
this study, we begin to address this by quantifying FAK phosphorylation
and ERK2 activation in response to manipulating
5
1 integrin interaction with its ligand, Fn.
The focus on FAK and ERK2 is based not only on their significance in
regulating multiple cell functions (10-14) but also on the controversy
surrounding the role of FAK as an upstream component in
integrin-mediated ERK2 activation (15-19). Therefore, in addition to
relating integrin-ligand binding to these signals in a dose-response signaling study, we compare the dynamic portions of FAK and ERK2 signals to determine whether the kinetics are reflective of FAK phosphorylation being upstream of ERK2 activation. Furthermore, by
undertaking this kinetic analysis, we aim to develop a rigorous methodology for quantitatively comparing signals that are
often-observed to be dynamic and diverse. For example, MAPK activity
was measured to be a transient response spanning 60 min in Swiss 3T3
fibroblasts but was long-lived in NIH3T3 cells, maintaining a nonbasal
steady-state level for up to 180 min (20, 21). Within the same cell
system, altering the form of stimulation produced a transient
versus sustained MAPK response (21). In addition, even for a
fixed stimulation in the same cell type, FAK phosphorylation and ERK2
activity followed disparate time courses (22). Given this diversity in
signaling responses, it is essential to determine what properties of
these signals can be used to ascertain latent correlations and to gain insight into the regulatory mechanisms, both positive and negative, affecting these signals.
In our system, analysis of the dynamics of the ERK2 and FAK response
revealed that (a) FAK and ERK2 activation by integrin/Fn binding may involve pathways having some parallel character;
(b) the initial rate of signaling via ERK2 is proportional
to integrin-ligand bond number; (c) ERK2 deactivation is
driven by feedback mechanisms operating at a rate determined by the
amount of active ERK2 and with a rate constant independent of
integrin/Fn binding; (d) despite the superficial disparity
in the FAK and ERK2 time courses, the initial rates of both responses
have a similar dependence on Fn density; and (e) the
disparity stems from different desensitization mechanisms regulating
FAK and ERK2. Finally, metrics proposed for representing these dynamic
signals were shown to quantitatively correlate to their common stimulus
of integrin/ligand binding and cell adhesion.
 |
MATERIALS AND METHODS |
Antibodies and Reagents--
Human plasma Fn and PL was obtained
from Sigma. The human
5 cDNA (23) and the 6F4 anti-human
5
antibody were gifts from Dr. Louis Reichardt (University of California,
San Fransisco, CA) and Dr. Ralph Isberg (Tufts University),
respectively. The sc-154 anti-ERK2 antibody was purchased from Santa
Cruz Biotechnology. The E10 monoclonal antibody (New England Biolabs)
was used to detect phospho-p44/42 MAP kinase, and total ERK1/2 amounts
were probed with the pan-ERK antibody (Transduction Laboratories). The
sc-558 anti-FAK antibody (Santa Cruz Biotech) and the 2A7 monoclonal
anti-FAK antibody (Upstate Biotechnology) were used for Western
blotting and immunoprecipitation, respectively.
Cell Culture--
CHO-B2 cells transfected with human
5
integrin subunit as described previously (24) were maintained under
selection with 500 µg/ml Geneticin (Life Technologies, Inc.) in
Dulbecco's modified Eagle's medium supplemented with 10% (v/v) fetal
bovine serum, 4 mM L-glutamine, 1 mM sodium pyruvate, and 1% (v/v) 100× nonessential amino
acids. CHO cells expressing human
5 integrin were divided into
subpopulations based on their
5
1 integrin
expression levels using fluorescence-activated cell sorting (24).
Sorted cells were grown and frozen for later use.
Protein-coating Surfaces and Quantification of Fn Coating
Density--
Fn or PL diluted in PBS was incubated overnight at
4oC in Nunc tissue culture-treated plastic dishes. The
dishes were then washed twice with cold PBS and blocked for 1 h at
37 °C with 2 mg/ml sterile-filtered, heat-inactivated
(70oC, 1 h) bovine serum albumin in PBS. Prior to use,
the dishes were washed twice with warm PBS.
Fn coating density was quantified using Fn labeled with
125I using the manufacturer's protocol for Iodobeads
(Pierce). Radioisotope-labeled Fn was coated onto Nunc tissue culture
plastic as described above, including the bovine serum albumin block
and the final two warm PBS washes. The Fn remaining on the dish was
removed using a series of incubations and washes with 1 M
NaOH and 10× trypsin (Sigma). Fluid from each wash and strip
incubation was collected, and the amount of radioactivity was measured
with a gamma counter (Packard).
Serum Starvation and Stimulation on Protein-coated
Surface--
Cells were serum-starved on 100-mm tissue culture dishes
for 18 h in serum-free media containing 25 mM
Hepes-based Dulbecco's modified Eagle's medium, 500 µg/ml
Geneticin, 4 mM L-glutamine, 1 mM
sodium pyruvate, 1% (v/v) 100× nonessential amino acids, and 2 mg/ml
bovine serum albumin. Cells were suspended using versene (Life
Technologies, Inc.) and resuspended in serum-free medium to a
concentration of 5 × 105 cells/ml. They were
maintained in suspension for 1 h to bring adhesion-related signals
to a basal level.
Serum-starved cells were plated onto Fn-coated 60-mm dishes and were
incubated at 37oC. At desired times, they were washed once
with cold PBS and lysed by adding cold lysis buffer containing 50 mM Tris (pH 7.5), 150 mM sodium chloride, 50 mM
-glycerophosphate (pH 7.3), 10 mM sodium pyrophosphate, 30 mM sodium fluoride, 1% Triton X-100, 1 mM benzamidine, 2 mM EGTA, 100 µM
sodium orthovanadate, 1 mM dithiothreitol, 10 µg/ml
aprotinin, 10 µg/ml, 1 µg/ml pepstatin, and 1 mM PMSF.
The lysis buffer for FAK studies was more stringent, containing 0.5% Nonidet P-40 and 0.25% sodium deoxycholate. Cells were scraped into
the buffer and allowed to lyse for approximately 15 min. Lysates were
centrifuged at 14,000 rpm for 15 min, and the supernatant was
collected. Micro-BCA protein determination (Pierce) was used to
determine total protein concentration.
ERK2 Kinase Activity and Phosphorylation Assay--
ERK2 kinase
activity was measured using a sensitive in vitro assay
performed in a 96-well format as described previously (25). Briefly,
anti-ERK2 antibody was coated on the surface of
Reacti-BindTM protein A-coated wells (Pierce) by incubating
wells with 10 µg/ml sc-154 antibody overnight at 4oC.
After the wells were washed, 25 µg of cell lysate was incubated for
3 h at 4oC. To measure background, an extra well was
incubated with just lysis buffer and was carried through the assay in
the same manner as other samples. After washing, each well was
resuspended in buffer containing 20 mM Tris (pH 7.5), 15 mM magnesium chloride, 5 mM
-glycerophosphate (pH 7.3), 1 mM EGTA, 0.2 mM sodium orthovanadate, and 0.2 mM
dithiothreitol. To each well, 40 µg of myelin basic protein (Sigma)
was added. The in vitro reaction was initiated by adding 25 µM ATP (1 µCi of [
-32P]ATP). After 30 min of agitation at 37 °C, reactions were quenched with 75 mM phosphoric acid. The quenched reaction contents were filtered through a 96-well phosphocellulose filter plate using the
Millipore Multiscreen® system (Millipore). After washes,
32P label on each filter paper was quantified using
CytoScintTM (ICN Biomedicals) scintillation fluid and
RackBeta (Wallac) scintillation counter. 32P measurements
were adjusted by subtracting the radioactivity associated with the
background sample.
For determining dually phosphorylated ERK1/2 levels, whole cell lysates
(15 µg) were resolved in 10% SDS-polyacrylamide gel electrophoresis
and blotted onto PVDF membrane. Blots were probed using 1:5000 dilution
of E10 anti-phospho-ERK1/2 antibody. After analyzing the blot, it was
stripped and reprobed for total ERK1/2 levels using 1:5000 dilution of
pan-ERK antibody.
FAK Phosphorylation Assay--
FAK was immunoprecipitated from
100 µg of cell lysate using ~2 µg of 2A7 anti-FAK antibody coated
on anti-mouse IgG beads (Sigma). After four washes, 30 µl of 1× SDS
sample buffer was added to the immunoprecipitate, and the sample was
boiled for 5 min. The sample was resolved under 7.5%
SDS-polyacrylamide gel electrophoresis and transferred onto
nitrocellulose membrane. Blots were probed for phosphotyrosine using
1:2500 dilution of RC20H and the SuperSignal® Ultra substrate
(Pierce). After analyzing the blot, it was stripped by incubating in
62.5 mM Tris-Cl, pH 6.8, 2% SDS, 100 mM
-mercaptoethanol at 60 °C for 30 min and probed for total FAK
using 1:100 dilution of sc-558 antibody. Bands were visualized with the
Molecular Imager® system (Bio-Rad), and further analysis and
quantification were performed with the Multi-Analyst® software
(Bio-Rad). FAK phosphorylation levels were normalized to the amount of
total FAK recovered from each immunoprecipitate.
Centrifuge Adhesion Assay--
Nunc tissue culture-treated
96-well plates were coated with varying amounts of Fn (5 wells for each
Fn amount). A set of negative-control wells with no Fn was also
prepared. A positive-control plate coated with 20 µg/ml PL was
prepared to support attachment of all plated cells.
Serum-starved cells were plated in these wells and allowed to adhere at
37 °C for 10 min. During the next 10 min, cells continued to adhere
to the surface while the plate was being prepared for centrifugation.
In total, cells were given 20 min to form their attachments to the
surface. The wells were prepared for centrifugation by filling them
completely with serum-free medium and sealing them. The plates
containing both the Fn-coated and negative-control wells were inverted
and centrifuged for 10 min at room temperature. The positive-control
plate was inverted but not centrifuged.
After centrifugation, the seals were removed, and the contents of all
wells were aspirated. While the plates were kept on ice, cells were
lysed for 5 min in 20 µl of cold 0.5% Triton X-100 in PBS. In the
meantime, lactate dehydrogenase reagent (Sigma) was prepared by mixing
10 parts reagent A to 0.4 parts reagent B. Lactate dehydrogenase
reagent was added to each well and the mixture was transferred to an UV
Spectra plate (Corning Costar). The absorption at 340 nm
(A340) was read for 3 min, every 12 s on a
Spectramax (Molecular Dynamics). The A340
readings for the negative-control wells were treated as background and
were subtracted from the other measurements. The rate of
A340 decrease is proportional to the number of
cells in each well. The fraction of cells detached due to
centrifugation was calculated as 1 minus the ratio of the rate of
A340 decrease in the wells that were centrifuged
to the rate of A340 decrease in the positive-control well. From this data, the mean detachment force required to detach 50% of the cells
was calculated.
Adhesion Wash Assay--
Serum-starved CHO cells were plated in
microtiter wells in serum-free medium with 1 mM RGD, 1 mM RGE, or no peptide. After allowing cells to adhere and
spread for 1 h, a picture was taken using a Nikon camera attached
to a phase-contrast microscope. Then, the plate was pulsed four times
at 800 rpm on a plate shaker to dislodge weakly adhered cells. After a
single wash with PBS, cell number was quantified using the lactate
dehydrogenase assay as described above.
 |
RESULTS |
Modulation of
5
1 Integrin and Fn
Levels--
To quantitatively relate integrin-ligand binding to
integrin-mediated signaling,
5
1
integrin-Fn binding was manipulated by altering both
5
1 integrin expression level and Fn
coating density. Two CHO cell populations with relative mean
5
1 integrin expression levels of 1 and
1.7 were obtained by fluorescence-activated cell sorting of a CHO-B2
cell line that was transfected with cDNA encoding the human
5
integrin subunit (Fig. 1).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 1.
CHO cells were sorted into 1× and 1.7×
relative 5 integrin subunit expression
levels. CHO-B2 cells were transfected with human 5 cDNA and
were sorted into subpopulations based on their 5 expression. These
sorted cells were grown and frozen for storage. After a passaging
scheme and serum-starvation protocol that was also used for each
signaling and adhesion experiment, the relative 5 expression levels
were checked by flow cytometry. A control sample (broken
line) with just secondary antibody treatment was used to determine
background fluorescence. The relative 5 1
integrin expression levels were determined to be 1× (thin solid
line) and 1.7× (heavy solid line).
|
|
The amount of adsorbed Fn was varied by incubating tissue culture
plastic with solutions of different fibronectin concentration. Radioisotope-labeled Fn was used to directly measure the amount of Fn
coated on the surface (Fig. 2). The
adsorption isotherm fit a curve described by the Langmuir model for
single species adsorption to a single site on the substratum, and
maximum coverage was predicted to be 2.2 (± 0.3) × 1010 molecules/mm2 or 16 (± 2.2)
ng/mm2, assuming a molecular mass of 450 kDa. This value is
in agreement with the theoretically predicted saturation density of
3.2 × 1010 molecules/mm2 from a
close-packing model that assumes cylindrical dimensions of length 60 nm
and base diameter 6 nm for the Fn molecule (26). Half-maximal
adsorption occurred at a coating concentration of 83 (± 20) µg/ml or
180 (± 43) nM. We used coating concentrations in the range
of 0.1-10 µg/ml yielding surface Fn densities of 5.3-310 × 107 molecules/mm2. Adsorption was not a linear
function of coating concentration as a 100-fold increase in coating
concentration yielded only a 60-fold increase in surface density,
indicating the importance of directly measuring levels of adsorbed
Fn.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 2.
Fibronectin adsorption was a nonlinear,
monotonically increasing function of coating concentration. After
coating tissue culture dishes with radioisotope-labeled fibronectin in
a manner consistent with surface preparation for signaling and adhesion
experiments, the amount of fibronectin adsorbed onto the surface was
quantified. The adsorption data was fit to a Langmuir single-site model
described by A = Amax · Cc/(Ka + Cc), where A is the amount of
adsorbed fibronectin, Cc is the coating
concentration, Amax is the surface density at
saturation, and Ka is the coating concentration
required to achieve half-maximal adsorption (r2 = 0.99).
Error bars represent the S.D. computed from three
independent experiments.
|
|
Magnitude and Kinetics of ERK2 Response Depend on Integrin-Ligand
Binding Properties--
Because our focus was to quantify signaling
induced specifically by
5
1 integrin-Fn
interactions, cells were stimulated by plating on Fn-coated surfaces
under serum-free conditions to avoid additive signaling effects from
growth factors and other ECM proteins present in serum. Signaling
synergy between growth factor receptors and integrins is well
documented and would thwart our ability to make clear conclusions about
signaling responses caused solely by the binding of
5
1 integrin to Fn (27-30).
In order to study the full effect of changing integrin-ligand binding
properties, the entire time course of the ERK2 signal was measured at
each condition. The challenge of such a study is that the number of
parameters was enlarged to include not only two
5
1 integrin expression levels and five Fn
amounts, but also several time points. In total, this involved ERK2
activity measurement of ~60 samples per trial. To handle such a large
quantity of samples, we developed and utilized a modified microtiter
ERK2 activity assay that allowed for convenient and concurrent
processing of multiple samples (25). Using this method, the measured
time course of ERK2 activity revealed quantitative variations in
response to changes in integrin-ligand binding properties (Fig.
3, A and B). This
observed ERK2 response was initiated specifically by cell adhesion to
Fn, as plating cells on PL failed to induce a response (Fig.
3C).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
Both the magnitude and the kinetics of the
ERK2 time course depends on 5 1
integrin expression level and fibronectin density. ERK2 activity
was measured in response to plating serum-starved CHO cells with
relative 5 1 integrin expression levels of
1× (A) and 1.7× (B) on surfaces with
fibronectin amounts (107 molecules/mm2) of 5.3 ( ), 13 ( ), 25 (×), 50 ( ), and 310 ( ). Error
bars represent the S.E. from two independent experiments.
C, ERK2 activation was mediated specifically by fibronectin
because a PL-coated surface fails to activate ERK2. Cells were plated
on a surface coated with either 0.5 µg/ml Fn or 5 µg/ml PL. After
10 min, cells were lysed, and levels of dually phosphorylated ERK1/2 in
15 µg of whole cell lysate were determined by Western blot. Total
ERK1/2 levels were the same for both cases as verified by stripping the
blot and reprobing with pan-ERK antibody.
|
|
For each integrin expression level, a change in Fn density altered both
the magnitude and kinetics of the ERK2 response. When Fn amount was
increased, ERK2 activity reached a higher peak level within a shorter
time. For example, for the 1×
5
1
expression level, an increase in Fn coating density from 5 × 107/mm2 to 310 × 107/mm2 increased the peak activity level
approximately 5-fold and reduced the time required to reach this peak
from ~10 to ~5 min. The initial rate of ERK2 activation affects
both the magnitude of the peak and the time required to reach this
peak. We calculated this initial ERK2 activation rate as the slope of
the time course between the 0- and 5-min time points. Higher initial
rates of ERK2 activation were achieved by an increase in not only
ligand density but also integrin expression. Normalizing the initial
rate to integrin expression collapses the rate data for the two
integrin expression levels onto a single curve, indicating that the
initial rate of ERK2 activation is directly proportional to integrin
amount (Fig. 4). At low Fn density, this
normalized rate was also proportional to Fn amount as shown by a linear
curve fit, revealing that the rate of ERK2 activation is simply
proportional to the product of the Fn and integrin amount. At high Fn
density, the initial rate of ERK2 activation saturated but was still
proportional to integrin amount. This shows that the intracellular
activation steps performed at a higher rate when more integrin was
provided for binding to Fn.

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 4.
The initial rate of ERK2 activation depends
on integrin-ligand binding properties. For each integrin
expression level and fibronectin amount, the initial rate of ERK2 was
calculated as the slope of the ERK2 activity time course between the 0- and 5-min time points. At each Fn density, this initial rate normalized
to the integrin expression level was the same value for the 1× ( )
and 1.7× ( ) integrin levels, indicating that the initial rate was
proportional to integrin expression level. For the lower levels of
ligand, a linear curve fit showed that the normalized rate was also
proportional to fibronectin density (r2 = 0.94).
|
|
Regardless of the peak level attained,
5
1
integrin-mediated ERK2 activation decays to a basal level by 20 min
(Fig. 3, A and B). This suggests that the rate of
ERK2 desensitization is proportional to ERK2 activity, which was
confirmed by fitting an exponential decay curve to this portion of the
ERK2 activity time course. Calculated decay constants for each Fn
coating density and integrin expression level fluctuated around a mean
value of 0.3 (± 0.08) min
1 and showed no significant
dependence on integrin-ligand binding properties (Table
I).
View this table:
[in this window]
[in a new window]
|
Table I
ERK2 deactivation is a first-order process with respect to ERK2
activity level
For each integrin expression level and fibronectin coating density, the
desensitization portion of the ERK2 activity time-course (time points
10, 15, and 20 min) was fit to an exponential decay, and the obtained
r2 values ranged from 0.94 to 0.99. The decay
constant fluctuated around a mean value of 0.30 (±0.08)
min 1. Values in parentheses indicate the S.E. of the fit for
the decay constant.
|
|
Excess Intracellular Machinery Permits Increased Overall ERK2
Response for Increased Integrin Expression Levels--
The integral of
the ERK2 time course was calculated as a single measure capable of
representing both the magnitude and duration of the transient ERK2
signaling response. This integrated ERK2 activity was plotted as a
function of Fn coating density for both integrin expression levels
(Fig. 5A). For a given
integrin amount, the integrated ERK2 response increased with increasing
Fn coating density, but saturated at high levels of Fn. This saturation
was caused by a limitation in integrin-ligand binding because even at
these higher saturating Fn densities, allowing more integrin-ligand bond formation by increasing integrin expression caused an increase in
the integrated ERK2 response. In fact, when the integrated ERK2
response was normalized to integrin expression level, the normalized
values for the 1× and 1.7× integrin expression levels were equal at
every Fn coating density, indicating that the overall ERK2 response was
directly proportional to integrin expression level (Fig.
5B). This direct proportionality indicates that when the
binding limitations were relaxed by an increase in integrin amount, the
intracellular signaling machinery was sufficiently in excess to promote
a proportionally higher ERK2 signal.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
The integrated ERK2 response saturated at
higher ligand density but increased when integrin expression was
raised. A, the integral of the ERK2 time course from 0 to 20 min was calculated for the 1× ( ) and 1.7× ( ) integrin
expression level using the trapezoidal rule: Integrated ERK2
response = (5 min) · (average(E0, E5) + average(E5, E10) + average(E10,
E15) + average(E15+ E20)), where
Ei is the ERK2 activity level at time i
for i = 0, 5, 10, 15, and 20 min. B, the
integrated ERK2 response, when normalized to the integrin expression
level, was equal for the 1× (open columns) and 1.7×
(filled columns) integrin expression levels at each
fibronectin coating density. This indicates that the overall ERK2
response was proportional to integrin amount. Error bars
represent the standard error for two independent experiments.
|
|
Initial Rates of Signaling via FAK and ERK2 Share Similar
Dependence on Integrin-Ligand Binding Properties--
To see whether
other integrin-mediated signals show similar dependence on
integrin-ligand binding, FAK phosphorylation was measured as a function
of time (Fig. 6A). The time
course of FAK phosphorylation significantly differed from the transient
pulse response observed for ERK2. Upon exposure to a Fn-coated surface, FAK phosphorylation levels increased for the first 60 min, after which
the response reached a suprabasal steady-state level that was
maintained for up to 3 h. Similar to the ERK2 response, this FAK
response required cell adhesion to Fn as PL failed to induce significant FAK phosphorylation above basal levels (Fig.
6B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 6.
The time course of integrin-mediated FAK
tyrosine phosphorylation differs from the ERK2 signaling response.
A, FAK phosphorylation increases to a nonbasal, steady-state
value within 60 min after plating cells on a Fn-coated surface. 1×
5 1 expressing CHO cells were plated on a
surface with a Fn density of 50 × 107/mm2. After indicated times, cells were
lysed, and immunoprecipitated (IP) FAK was analyzed for
phosphotyrosine content by Western blot (WB). Phosphorylated
FAK values were normalized to the total amount of immunoprecipitated
FAK, as determined by probing the stripped blot with an anti-FAK
antibody. Also depicted for comparison is the ERK2 response upon
plating cells on the same Fn density. B, cell interaction
with fibronectin, but not PL, stimulated significant FAK
phosphorylation above the basal level. Cells were plated on a surface
coated with either 0.5 µg/ml Fn or 5 µg/ml PL. After 10 min, cells
were lysed, and the level of FAK phosphorylation was measured.
|
|
Despite the disparate contours of the FAK phosphorylation and ERK2
activity time courses, the two signals were found to have a similar
dependence on integrin-ligand binding properties, as revealed by
analysis of the initial rates of FAK phosphorylation. The initial rate
of FAK phosphorylation was captured by a single measure of FAK
phosphorylation level at an early time point (7.5 min), during which it
was still increasing in a linear fashion. For both integrin expression
levels, the initial rate of FAK phosphorylation and ERK2 activation
were found to be similar functions of Fn density (Fig.
7). As with ERK2, the initial rate of FAK
phosphorylation increased for lower Fn levels and saturated at high Fn
surface density, presumably due to limitations in integrin-ligand
bond formation.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 7.
Initial rate of ERK2 activation and FAK
phosphorylation show a similar dependence on Fn density. Initial
rate of FAK phosphorylation was represented by an early time point (7.5 min) measurement of FAK phosphorylation level by Western blot. The
percent maximal rate of ERK2 activation ( ) and FAK phosphorylation
( ) were determined for 1× (A) and 1.7× (B)
integrin expression levels as a function of Fn amount.
|
|
Proposed Metrics for FAK and ERK2 Signals Correlate to
Cell-Substratum Adhesivity--
In contrast to requiring the
integrated activity as a representative measure of the ERK2 pulse
response, the steady-state FAK phosphorylation level can be used to
represent the overall FAK response. This steady-state value was
measured 90 min after plating cells on a Fn-coated surface. These
metrics of the overall FAK and ERK2 signaling response were found to
show similar dependence on Fn amount (Fig.
8, A and B). For
low Fn density, an increase in Fn amount resulted in a corresponding
increase in both the integrated ERK2 response and the steady-state FAK
phosphorylation level. In addition, both these overall responses
saturated at similar values of high Fn density.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 8.
Integrin-mediated signaling via ERK2 and FAK
correlate with short term cell-substratum adhesivity.
The integrated ERK2 response ( ) and steady-state FAK phosphorylation
( ) correlate with short term cell-substratum adhesivity ( ). CHO
cells with 1× (A) and 1.7× (B) relative
expression levels of 5 1 integrin were
plated on fibronectin-coated surfaces. The overall ERK2 response was
calculated as the integral of the ERK2 time course. Steady-state FAK
phosphorylation levels were measured 90 min after plating cells. For
short term adhesion measurements, a centrifugation detachment assay was
performed. The integrated ERK2 response ( ) and steady-state FAK
phosphorylation levels (- - - -) were fit to a saturation curve
as a function of Fn amount. C, cell adhesion required
integrin-fibronectin interaction because the absence of Fn or the
presence of soluble RGD peptide was able to block adhesion and
spreading. 1× 5 1 integrin-expressing CHO
cells were plated in microtiter wells either with or without 25 × 107 molecules/mm2 Fn coating. Those wells that
were coated with Fn were also supplied with 1 mM soluble
RGD, 1 mM soluble RGE, or no peptide. After 1 h,
pictures were taken of a representative view using a phase-contrast
microscope. The brightness and contrast of the scanned images were
enhanced using Adobe Photoshop. After the 1-h incubation, a wash assay
was performed to quantify adhesion. Results are expressed as a
percentage of the total number of cells plated.
|
|
Similar to signaling, adhesion was specifically mediated by
5
1 integrin-Fn interactions as either
soluble RGD (Fig. 8C) or anti-human
5
antibody (data not shown) was able to inhibit cell adhesion to a
Fn-coated substratum. This permitted a direct test of whether
integrin-Fn binding was the limiting factor for signaling by measuring
short term adhesion strength, a value shown to relate to
integrin-ligand bond number (24). Due to the sensitivity limit of the
centrifugation adhesion assay, adhesive strength given by the mean
detachment force was immeasurable for Fn density below ~10 × 107 molecules/mm2. Beyond this threshold
density, mean detachment force increased initially with increasing Fn
density until saturating at higher Fn amount (Fig. 8, A and
B). When the short term cell-substratum adhesivity is
compared with the overall FAK and ERK2 signaling responses, it is
evident that integrin-ligand bond formation and adhesion directly
correlate to the metrics of the FAK and ERK2 signals. In fact,
half-maximal mean detachment force, steady-state FAK phosphorylation,
and integrated ERK2 activity occurred at similar ligand coating
densities in the range of 5-15 × 107
molecules/mm2. At high ligand density, saturation of FAK
and ERK2 signaling corresponds to the saturation of adhesion,
confirming that signaling was constrained by integrin-ligand binding limitations.
 |
DISCUSSION |
Integrin-mediated signaling involves a complex array of molecules
working among synergistic pathways to regulate cell processes. In
addition to the complexity of the interconnected biochemical pathways,
there may be biophysical constraints on events that are required for
maximal signal transduction, such as the aggregation of ligand-occupied
integrins and the recruitment of proteins to these aggregated complexes
(7, 9). Diffusion or molecular crowding may limit the formation of
protein-protein associations and affect activation of downstream
components (8). Because the likely complex interplay within this
integrated signaling network is not well understood, it is not
intuitively apparent how the extracellular integrin-ligand binding
event relates to intracellular signaling responses. In this study, we
addressed this issue by quantifying FAK and ERK2 signaling in response
to manipulating
5
1 integrin interaction
with Fn under serum-free conditions, thereby eliminating complicating
effects from growth factors and other ECM proteins in serum.
5
1 integrin interaction with Fn produced
a transient biphasic ERK2 response with time, regardless of integrin
and Fn amount (Fig. 3, A and B). This biphasic
response results from a balance between pathways that activate and
deactivate ERK2. To better understand the positive and negative
mechanisms regulating ERK2, we divided our analysis of the signal into
two parts. First, to gather insight into the activation mechanisms, the
focus was placed on the early part of the response before negative
regulation of the signal becomes significant. At these early times, the
rate of activation evidently outweighed that of deactivation and ERK2 activity was observed to increase. Several proteins, including p130Cas,
Crk, FAK, paxillin, Rho, and Shc, have been identified in pathways
leading to integrin-mediated ERK2 activation (3, 5, 7, 15).
Furthermore, because Fn possesses other signal-generating domains, such
as the heparin-binding domain (31), integrin binding to Fn may initiate
an ERK2 response by exposing cryptic sites on Fn that interact with a
secondary receptor that directly activates ERK2. Despite the complex
involvement of several pathways and molecules leading to ERK2
activation, the observed rate of increase in ERK2 activity was simply
proportional to both integrin and Fn levels at low Fn density (Fig.
4).
The simplicity of this dependence gives insight into the cumulative
performance of these activation pathways. During the period of initial
cell-surface contact, it can be assumed that the number of free
integrins is much greater than the number of integrin-Fn complexes and
can be treated as a constant with a value approximately equal to the
total number of integrins on the cell surface. This assumption also
implies that the rate of bond dissociation is relatively small compared
with the rate of bond formation. In this case, the number of
integrin-Fn bonds would be proportional to the product of the integrin
and Fn amounts. Because the rate of increase in ERK2 activity was also
a linear function of this product, the initial rate of ERK2 activation
seems to be proportional to the number of integrin-ligand complexes at
low ligand density. At high ligand density, the rate of increase in
ERK2 activity saturates. However, even in this regime, the rate
increases when integrin amount is increased, suggesting that ERK2
activation is limited by integrin expression and not by intracellular
signaling processes.
In the second deactivation-dominated phase, two types of negative
feedback mechanisms may be responsible for the observed decay in ERK2
signal. The first involves proteins that catalyze the direct
deactivation of ERK2 by dephosphorylation of its tyrosine and threonine
residues, including dual specificity phosphatases, such as MKP-1,
MKP-2, MKP-3, and PAC-1 (32). Although this phosphatase-mediated deactivation is essential to reduce ERK2 activity levels, these phosphatases would have to function at a rate high enough to surpass the growing impetus for ERK2 activation, as the cells continue to
spread and form new integrin-ligand bonds even during the ERK2 signal
decay phase. To reduce the load on these phosphatases, a second set of
feedback mechanisms may disconnect the sequence of pathways that link
the integrin-ligand binding event to the ERK2 signal, thereby
countering further ERK2 activation by newly formed integrin-ligand
bonds. Several such decoupling mechanisms have been reported that
target a number of components upstream of ERK2, including
serine/threonine phosphorylation of a proline-rich carboxyl-terminal
domain of Sos, hyperphosphorylation of Raf, and phosphorylation on two
threonine residues of MEK (33-36).
Instead of focusing on the details of each potential feedback pathway,
our aim was to gain quantitative insight into the overall performance
of these feedback mechanisms. An interesting result from our
quantitative measurements was that regardless of the magnitude of the
ERK2 signal, the desensitization was achieved within the same amount of
time. Thus, a higher magnitude of ERK2 signal was countered by a
proportionally higher magnitude of desensitization in order to reduce
the signal in the same time span, a feature indicative of a first-order
decay process. An exponential curve fit to the decay portion of the
ERK2 time course revealed that the rate of decay was proportional to
the ERK2 activity level with a decay constant of 0.3 (± 0.08)
min
1 (Table I). Therefore, without detailed knowledge of
the combination of direct deactivation and/or decoupling events leading
to ERK2 signal decay in this system, these feedback processes were
shown to perform collectively at a rate determined by the level of
active ERK2.
Because ERK2 activation has been shown to be both dependent and
independent of FAK in various studies (15-19), the kinetics of FAK
phosphorylation was analyzed in order to ascertain the role of FAK as
an upstream regulator of ERK2 activity in our system. In contrast to
the ERK2 pulse-like response, FAK phosphorylation increased to a
suprabasal steady state level after 60 min of stimulation on a
Fn-coated surface (Fig. 6A). Perhaps surprisingly, the
initial increase of ERK2 activity is faster than that of FAK
phosphorylation. Furthermore, there was no apparent time lag between
the phosphorylation of FAK and the activation of ERK2, as would be
expected if FAK phosphorylation were upstream of ERK2 activation. But
the absence of this time lag could be attributed to insufficient time
resolution of the very early data. Nevertheless, these two observations
raise the possibility that FAK-independent pathway(s) may lead to ERK2 activation. However, it can also be argued that ~20% of maximal FAK
phosphorylation is present even at time zero, and this may be
sufficiently beyond a threshold level of FAK phosphorylation required
to stimulate ERK2. Kinetic arguments such as these can be strengthened
if the absolute levels, instead of relative values, of phosphorylated
FAK and ERK2 activity can be measured. Then, questions such as whether
there is a sufficient number of phosphorylated FAK molecules to
generate an observed number of active ERK2 molecules can be addressed
and thereby shed insight into both the pathway mechanisms and the
stoichiometry of the components in these pathways.
Although our data may bring into question whether FAK phosphorylation
definitively lies upstream of ERK2 activation or whether these two
signaling events lie in parallel pathways, it is apparent from controls
(Figs. 3C and 6B) that these two signals are
initiated by a common integrin-ligand binding event and not by adhesion to PL-coated surfaces. However, the apparent disparity in the FAK and
ERK2 time courses is not intuitively consistent with the fact that both
these signaling responses share the same integrin-Fn binding stimulus.
Because later desensitization effects can cloud the link between the
stimulus and intracellular signal, we first focused on the early
portion of the FAK and ERK2 signals. The initial rates of FAK
phosphorylation and ERK2 activation showed a similar dependence on
integrin-ligand binding properties (Fig. 7), indicative of their shared
stimulus. Therefore, it is likely that the two signaling time courses
diverge due to differential regulation of desensitization of FAK
phosphorylation versus ERK2 activation. Net integrin-ligand
bond formation persists as the cells continue to spread until reaching
final morphology near 60 min after plating (visual observations, data
not shown). Whereas FAK phosphorylation could be coincident with cell
spreading and integrin-ligand bond formation, ERK2 activity, as
discussed previously, decays from its peak at 10 min to basal levels by
20 min. This suggests that the pathways connecting integrin-ligand bond
formation to FAK phosphorylation are not disconnected by feedback
pathways, whereas those linking integrins to ERK2 activation are
rapidly decoupled.
These kinetic analyses of different portions of the FAK and ERK2 signal
lend insight into the activation and desensitization mechanisms but
cannot immediately identify the "information content" of a signal.
That is, what characteristic measure of the signal is representative of
the information carried by that signal to affect downstream cell
functions? Consider first the transient ERK2 pulse response and what
aspect of this signal can be used to represent the entire signal (Fig.
3, A and B). Its activity at a single time point
is not a suitable representation of the entire response, because both
the magnitude and kinetics are affected by changes in integrin-ligand
binding properties. For example, choosing one particular early time
point, such as 5 min, would underestimate the signal because the peak
activity had not yet occurred. Picking a time point associated with the
peak level is not a feasible option because the time at which this peak
occurred shifts in response to changes in integrin expression and Fn
density. Choosing a late time point, such as 20 or 40 min, to measure
steady-state ERK2 activity level would lead to the erroneous conclusion
that there is no ERK2 response to plating cells on Fn. Furthermore, in
physiological terms, the ERK2 activity level at a single time point
during a transient response has little significance, because it is
possible that ERK2 affects its downstream components each minute that
it is active. Therefore, we proposed the integral of the ERK2 activity
level as the measure of the overall signaling response for a transient
pulse-like signal, because it accounts for the duration of the signal
in addition to its magnitude. Furthermore, this integrated amount of
activity accounts for shifts in kinetics because the entire time course
is used to calculate this value. In contrast, a different approach
seems appropriate for signals, such as FAK, phosphorylation that
maintain a nonbasal steady-state level. Here, one can argue that the
physiologically relevant measure would be its steady-state
phosphorylation level, because the phosphorylated signaling molecule
has the potential to scaffold with its downstream components as long as
it remains phosphorylated.
These two measures were applied to encapsulate the overall FAK and ERK2
signal, and these overall measures were found to correlate with cell
adhesion (Fig. 8). For each integrin expression level, the integrated
ERK2 response and the steady-state FAK phosphorylation level were
increasing monotonic functions of Fn density that saturated at high Fn
amount. This saturation paralleled the saturation of short term
adhesion, indicating that integrin-ligand binding was the limiting
factor in signaling via FAK and ERK2. Even at saturated levels at
high ligand density, an increase in integrin expression produced a
proportional increase in ERK2 signal, revealing that the intracellular
machinery responsible for the ERK2 response is sufficiently in excess
to generate more signal once this binding limitation was released by
increasing the integrin expression level.
This type of quantitative analysis to other systems can be used to
identify bottlenecks in signaling pathways. These limiting factors or
events could be powerful disease therapy targets, as relieving or
further constricting these bottlenecks would be the most efficient way
to enhance or diminish information transfer to a downstream signal.
Furthermore, we have implemented an approach of dissecting dynamic
signals into their early and late segments to determine the
quantitative characteristics of the activation and deactivation
mechanisms, which would remain elusive to cursory inspection of
disparate time courses. Finally, the rapidly growing interest in
signaling ultimately stems from a need to relate these signals to
downstream cell processes. To do this, we must identify appropriate
metrics of a signal that best correlate to cell behavior, because this
would define what aspect of a signal needs to be manipulated to affect
downstream cell responses. For such a task, we propose here approaches
for two distinct signaling responses. For a pulse-like ERK2 response, a
first-time approach of using the integral of its activity was effective
in capturing both the duration and magnitude of the signal. On the
other hand, for signals such as FAK, the steady-state value may be a
valid representation of the signal, because this active/phosphorylated
level would be available to continuously work on its downstream target.
Future work will focus on whether these proposed or other single-value metrics for encapsulating a dynamic signal generated by both integrins and growth factors can adequately correlate to downstream cell functions and thus be used as parameters in predictive models relating
signaling and cell behavior. Such models may provide a rational basis
for the design of biomimetic surfaces that specifically activate
desired integrin signals or for the determination of target signaling
molecules for disease therapies.
 |
ACKNOWLEDGEMENTS |
We thank Jason Haugh and David Schaffer for
useful discussions.
 |
FOOTNOTES |
*
This work was funded by NIGMS, National Institutes of Health
Grants 53905 (to D. A. L.) and 23244 (to A. F. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Partially supported by the National Institutes of Health
Biotechnology Training Grant at the Massachusetts Institute of
Technology and by a grant from Johnson & Johnson Professional, Inc.
¶
Present address: Department of Biomedical Engineering, The
Johns Hopkins University, Baltimore, MD 21205.
**
To whom correspondence should be addressed. Tel.: 617-252-1629;
Fax: 617-258-0204; E-mail: lauffen@mit.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
ECM, extracellular
matrix;
FAK, focal adhesion kinase;
ERK, extracellular signal-regulated
kinase;
CHO, Chinese hamster ovary;
MAPK, mitogen-activated protein
kinase;
PBS, phosphate-buffered saline;
MEK, MAP kinase kinase;
PL, poly-L-lysine;
Fn, fibronectin.
 |
REFERENCES |
| 1.
|
Hynes, R. O.
(1992)
Cell
69,
11-25[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Lauffenburger, D. A.,
and Horwitz, A. F.
(1996)
Cell
84,
359-369[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Clark, E. A.,
and Brugge, J. S.
(1995)
Science
268,
233-239[Abstract/Free Full Text]
|
| 4.
|
Horwitz, A. F.
(1997)
Sci. Am.
276,
68-75[Medline]
[Order article via Infotrieve]
|
| 5.
|
Schwartz, M. A.,
Schaller, M. D.,
and Ginsberg, M. H.
(1995)
Annu. Rev. Cell Dev. Biol.
11,
549-599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Varner, J. A.,
and Cheresh, D. A.
(1996)
Curr. Opin. Cell Biol.
8,
724-730[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Burridge, K.,
and Chrzanowska-Wodnicka, M.
(1996)
Annu. Rev. Cell Dev. Biol.
12,
463-519[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Bray, D.
(1998)
Annu. Rev. Biophys. Biomol. Struct.
27,
59-75[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Miyamoto, S.,
Teramoto, H.,
Coso, O. A.,
Gutkind, J. S.,
Burbelo, P. D.,
Akiyama, Y.,
and Yamada, K. M.
(1995)
J. Cell Biol.
131,
791-805[Abstract/Free Full Text]
|
| 10.
|
Guan, J.-L.
(1997)
Matrix Biol.
16,
195-200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Klemke, R. L.,
Cai, S.,
Giannini, A. L.,
Gallagher, P. J.,
de Lanerolle, P.,
and Cheresh, D. A.
(1997)
J. Cell Biol.
137,
481-492[Abstract/Free Full Text]
|
| 12.
|
Mainiero, F.,
Murgia, C.,
Wary, K. K.,
Curatola, A. M.,
Pepe, A.,
Blumember, M.,
Westwick, J. K.,
Der, C. J.,
and Giancotti, F. G.
(1997)
EMBO J.
16,
2365-2375[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Pozzi, A.,
Wary, K. K.,
Giancotti, F. G.,
and Gardner, H. A.
(1998)
J. Cell Biol.
142,
587-594[Abstract/Free Full Text]
|
| 14.
|
Sastry, S. K.,
Lakonishok, M.,
Wu, S.,
Truong, T. Q.,
Huttenlocher, A.,
Turner, C. E.,
and Horwitz, A. F.
(1999)
J. Cell Biol.
144,
1295-1309[Abstract/Free Full Text]
|
| 15.
|
Giancotti, F. G.
(1997)
Curr. Opin. Cell Biol.
9,
691-700[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Lin, T. H.,
Aplin, A. E.,
Shen, Y.,
Chen, Q.,
Schaller, M.,
Romer, L.,
Aukhil, I.,
and Juliano, R. L.
(1997)
J. Cell Biol.
136,
1385-1395[Abstract/Free Full Text]
|
| 17.
|
Schlaepfer, D. D.,
Hanks, S. K.,
Hunter, T.,
and van der Geer, P.
(1994)
Nature
372,
786-791[Medline]
[Order article via Infotrieve]
|
| 18.
|
Schlaepfer, D. D.,
and Hunter, T.
(1996)
Mol. Cell. Biol.
16,
5623-5633[Abstract]
|
| 19.
|
Wary, K. K.,
Mariotti, A.,
Zurzolo, C.,
and Giancotti, F. G.
(1998)
Cell
94,
625-634[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Chen, Q.,
Kinch, M. S.,
Lin, T. H.,
Burridge, K.,
and Juliano, R. L.
(1994)
J. Biol. Chem.
269,
26602-26605[Abstract/Free Full Text]
|
| 21.
|
Zhu, X.,
and Assoian, R. K.
(1995)
Mol. Biol. Cell
6,
273-282[Abstract]
|
| 22.
|
Schlaepfer, D. D.,
Jones, K. C.,
and Hunter, T.
(1998)
Mol. Cell. Biol.
18,
2571-2585[Abstract/Free Full Text]
|
| 23.
|
Argraves, W. S.,
Suzuki, S.,
Arai, H.,
Thompson, K.,
Pierschbacher, M.,
and Ruoslahti, E.
(1987)
J. Cell Biol.
105,
1183-1190[Abstract/Free Full Text]
|
| 24.
|
Palecek, S. P.,
Loftus, J. C.,
Ginsberg, M. H.,
Lauffenburger, D. A.,
and Horwitz, A. F.
(1997)
Nature
385,
537-540[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Asthagiri, A. R.,
Horwitz, A. F.,
and Lauffenburger, D. A.
(1999)
Anal. Biochem.
269,
342-347[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
DiMilla, P. A.,
Albelda, S. M.,
and Quinn, J. A.
(1992)
J. Colloid Interface Sci.
153,
212-225[CrossRef]
|
| 27.
|
Lin, T. H.,
Chen, Q.,
Howe, A.,
and Juliano, R. L.
(1997)
J. Biol. Chem.
272,
8849-8852[Abstract/Free Full Text]
|
| 28.
|
Miyamoto, S.,
Teramoto, H.,
Gutkind, J. S.,
and Yamada, K. M.
(1996)
J. Cell Biol.
135,
1633-1642[Abstract/Free Full Text]
|
| 29.
|
Plopper, G. E.,
McNamee, H. P.,
Dike, L. E.,
Bojanowski, K.,
and Ingber, D. E.
(1995)
Mol. Biol. Cell
6,
1349-1365[Abstract]
|
| 30.
|
Renshaw, M. W.,
Ren, X.-D.,
and Schwartz, M. A.
(1997)
EMBO J.
16,
5592-5599[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Bloom, L.,
Ingham, K. C.,
and Hynes, R. O.
(1999)
Mol. Biol. Cell
10,
1521-1536[Abstract/Free Full Text]
|
| 32.
|
Lewis, T. S.,
Shapiro, P. S.,
and Ahn, N. G.
(1998)
Adv. Cancer Res.
74,
49-139[Medline]
[Order article via Infotrieve]
|
| 33.
|
Brunet, A.,
Pages, G.,
and Poussegur, J.
(1994)
FEBS Lett.
346,
299-303[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Buday, L.,
Warne, P. H.,
and Downward, J.
(1995)
Oncogene
11,
1327-1331[Medline]
[Order article via Infotrieve]
|
| 35.
|
Langlois, W. J.,
Sasaoka, T.,
Saltiel, A. R.,
and Olefsky, J. M.
(1995)
J. Biol. Chem.
270,
25320-25323[Abstract/Free Full Text]
|
| 36.
|
Wartmann, M.,
Hofer, P.,
Turowski, P.,
Saltiel, A. R.,
and Hynes, N. E.
(1997)
J. Biol. Chem.
272,
3915-3923[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit